Nothing Special   »   [go: up one dir, main page]

MX2015007916A - Peri-carbinoles. - Google Patents

Peri-carbinoles.

Info

Publication number
MX2015007916A
MX2015007916A MX2015007916A MX2015007916A MX2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A
Authority
MX
Mexico
Prior art keywords
carbinols
peri
reducing
symptom
risk
Prior art date
Application number
MX2015007916A
Other languages
English (en)
Inventor
Thomas A Jordan
John Clifford Chabala
Ke-Qing Ling
William A Kinney
Original Assignee
Aldeyra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldeyra Therapeutics Inc filed Critical Aldeyra Therapeutics Inc
Publication of MX2015007916A publication Critical patent/MX2015007916A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención está dirigida a compuestos de fórmula (I) (ver Fórmula) composiciones farmacéuticas, y métodos de uso para el tratamiento, reducción de síntomas de o reducción del riesgo de degeneración macular.
MX2015007916A 2012-12-20 2013-12-19 Peri-carbinoles. MX2015007916A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740197P 2012-12-20 2012-12-20
PCT/US2013/076592 WO2014100425A1 (en) 2012-12-20 2013-12-19 Peri-carbinols

Publications (1)

Publication Number Publication Date
MX2015007916A true MX2015007916A (es) 2016-04-07

Family

ID=50979217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007916A MX2015007916A (es) 2012-12-20 2013-12-19 Peri-carbinoles.

Country Status (14)

Country Link
US (1) US9604997B2 (es)
EP (1) EP2935220A4 (es)
JP (1) JP2016503797A (es)
KR (1) KR20150118106A (es)
CN (1) CN105073714A (es)
AU (1) AU2013361314A1 (es)
CA (1) CA2896032A1 (es)
CL (1) CL2015001754A1 (es)
HK (1) HK1217325A1 (es)
IL (1) IL239178A0 (es)
MX (1) MX2015007916A (es)
RU (1) RU2015120478A (es)
SG (1) SG11201504859YA (es)
WO (1) WO2014100425A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
IL296551B2 (en) 2012-12-21 2024-04-01 Janssen Biopharma Llc Nucleosides, modified nucleotides and their analogs
AU2014209387B2 (en) 2013-01-23 2018-11-01 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
KR20150120380A (ko) 2013-01-25 2015-10-27 알데이라 테라퓨틱스, 아이엔씨. 황반 변성의 치료에서 신규한 트랩
JP6959650B2 (ja) * 2015-08-21 2021-11-02 アルデイラ セラピューティクス， インコーポレイテッド アルデヒドコンジュゲートおよびその使用
CN108135907A (zh) * 2015-08-21 2018-06-08 奥尔德拉医疗公司 氘化化合物和其用途
EP3419633A4 (en) 2016-02-28 2019-10-30 Aldeyra Therapeutics, Inc. TREATMENT OF ALLERGIC EYE DISEASES WITH CYCLODEXTRINS
MX2018013472A (es) 2016-05-09 2019-02-28 Aldeyra Therapeutics Inc Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
EP3500256A4 (en) * 2016-08-22 2020-01-08 Aldeyra Therapeutics, Inc. ALDEHYDE CAPTURE CONNECTIONS AND USES THEREOF
JP2020511461A (ja) 2017-03-16 2020-04-16 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
WO2020068986A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
JP2022526917A (ja) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. PHARMACEUTICAL FORMULATIONS AND USES THEREOF
KR20230041021A (ko) 2020-07-16 2023-03-23 더마반트 사이언시즈 게엠베하 이소퀴놀린 화합물 및 AhR 불균형 치료에 있어서 그의 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
AU641052B2 (en) 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
EP0925282A1 (en) 1996-08-01 1999-06-30 Dowelanco 4-substituted quinoline derivatives having fungicidal activity
EP0980362B1 (de) 1997-05-02 2006-08-16 Schering Aktiengesellschaft Substituierte heterocyclen und deren verwendung in arzneimitteln
EP1080068A1 (en) 1998-03-12 2001-03-07 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
AU1735001A (en) 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20060281821A1 (en) 2003-03-14 2006-12-14 Krzysztof Palczewski Retinoid replacements and opsin agonists and methods for the use thereof
CA2527175A1 (en) 2003-04-18 2004-10-28 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2005035506A1 (ja) 2003-10-15 2005-04-21 Ube Industries, Ltd. 新規インダゾール誘導体
AU2004293105B2 (en) 2003-11-20 2010-09-09 Othera Holding, Inc. Amelioration of macular degeneration and other ophthalmic diseases
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
RU2006133300A (ru) 2004-02-17 2008-03-27 Президент Энд Феллоуз Оф Гарвард Колледж (Us) Управление течением офтальмологических расстройств, включая дегенерацию желтого пятна
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
CA2585210A1 (en) * 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
CN101987849B (zh) * 2006-04-14 2013-05-08 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性(amd)的方法
RU2009106461A (ru) 2006-07-25 2010-08-27 Энвиво Фармасьютикалз, Инк. (Us) Хинолиновые производные
RU2541430C2 (ru) 2007-10-05 2015-02-10 Акусела Инк. Композиции и способы лечения нейродегенеративных заболеваний
RU2011109190A (ru) 2008-08-12 2012-09-20 Сертрис Фармасьютикалз, Инк. (Us) Бензоксазолы, бензтиазолы и родственные аналоги в качестве модуляторов сиртуина
WO2010133672A1 (en) * 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
EP2477594A4 (en) 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
AU2010328186B2 (en) 2009-12-08 2014-12-18 Case Western Reserve University Compounds and methods of treating ocular disorders
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
MX346387B (es) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
WO2012105887A1 (en) 2011-01-31 2012-08-09 Tim Bowden Active principle for mitigating undesired medical conditions
WO2015187942A1 (en) 2014-06-04 2015-12-10 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
AU2014209387B2 (en) 2013-01-23 2018-11-01 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
KR20150120380A (ko) 2013-01-25 2015-10-27 알데이라 테라퓨틱스, 아이엔씨. 황반 변성의 치료에서 신규한 트랩
US10363231B2 (en) 2014-11-24 2019-07-30 Case Western Reserve University Compounds and methods of treating ocular disorders

Also Published As

Publication number Publication date
EP2935220A1 (en) 2015-10-28
CA2896032A1 (en) 2014-06-26
WO2014100425A1 (en) 2014-06-26
US20150344432A1 (en) 2015-12-03
HK1217325A1 (zh) 2017-01-06
SG11201504859YA (en) 2015-07-30
CN105073714A (zh) 2015-11-18
IL239178A0 (en) 2015-07-30
KR20150118106A (ko) 2015-10-21
CL2015001754A1 (es) 2015-11-06
AU2013361314A1 (en) 2015-07-02
JP2016503797A (ja) 2016-02-08
EP2935220A4 (en) 2016-04-27
RU2015120478A (ru) 2017-01-25
US9604997B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
MX2015007916A (es) Peri-carbinoles.
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
PH12017502141A1 (en) Compounds and their methods of use
IN2015DN01156A (es)
PH12015501385A1 (en) Autotaxin inhibitors
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX2015012478A (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
MD20150048A2 (ro) Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K
IN2015DN01151A (es)
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX362879B (es) Usos novedosos.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
PH12014501712A1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
PH12014502065A1 (en) Vesicular formulations
MX2015012343A (es) Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa.
IN2014DN08443A (es)
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
PH12015502703A1 (en) Pharmaceutical compositions
IN2014DN10683A (es)
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy